(-)-Ecopipam hydrochloride | 190133-94-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: (-)-Ecopipam hydrochloride
• 英文别名: trans-(-)-(6aS,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepine-12-ol hydrochloride；(-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naphtho-(2,1-b)azepine hydrochloride；(-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naphtho[2,1-b]azepine hydrochloride；(-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]-naphto-[2,1-b]azepine HCl；ecopipam hydrochloride；SCH 39166 HCl；(6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol;hydrochloride
• CAS: 190133-94-9
• 化学式: C₁₉H₂₀ClNO*ClH
• 分子量: 350.288
• InChiKey: APFMVAHRFWBCDG-JUOYHRLASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  23
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  23.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,2,3,4-四氢-1-萘酚 在 叔丁胺硼烷络合物 、 正丁基锂 、 甲烷磺酸 、 Jacobsen's catalyst 、 copper(l) cyanide 、 potassium carbonate 、 对甲苯磺酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 正己烷 、 甲基叔丁基醚 、 二乙二醇二甲醚 、 水 、 甲苯 为溶剂， 反应 59.25h， 生成 (-)-Ecopipam hydrochloride
  参考文献：
  名称：

  开发用于制备 Sch 39166 的高效工艺：规模化氮丙啶化学

  摘要：

  优化并放大了基于氮丙啶离子与格氏试剂的区域和立体选择性开环的三环 D1/D5 多巴胺拮抗剂的大规模合成。

  DOI：

  10.1021/op0402026

文献信息

• Process for synthesis of D1 receptor antagonists
  申请人：Schering Corporation

  公开号：US20030199690A1

  公开（公告）日：2003-10-23

  In one embodiment, the present invention describes the synthesis of a compound of formula 1 and intermediates therefor.

  在一种实施方式中，本发明描述了化合物formula1的合成及其中间体。
• ECOPIPAM FOR TREATMENT OF TOURETTES SYNDROME
  申请人：Emalex Biosciences, Inc.

  公开号：EP3919060A1

  公开（公告）日：2021-12-08

  The present invention encompasses methods of treating a subject who has been diagnosed as having a tic disorder or a movement disorder. The tic disorder can be Tourette's Syndrome, and the methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount of composition comprising a D1/D5 receptor antagonist, a D1/D5 receptor partial agonist, or a mixture thereof. For example, the D1/D5 receptor antagonist can be ecopipam or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, structural analog, metabolite, or polymorph thereof.

  本发明包括治疗被诊断为抽动障碍或运动障碍的受试者的方法。抽动障碍可以是抽动秽语综合征，方法可以包括以下步骤(a) 确定需要治疗的受试者；以及 (b) 向受试者施用治疗有效量的组合物，该组合物包含 D1/D5 受体拮抗剂、D1/D5 受体部分激动剂或其混合物。例如，D1/D5受体拮抗剂可以是依可比泮或其药学上可接受的盐、溶液剂、水合物、原药、结构类似物、代谢物或多晶型物。
• FUSED BENZAZEPINES FOR TREATMENT OF TOURETTE'S SYNDROME
  申请人：Psyadon Pharmaceuticals, Inc.

  公开号：EP2872145A1

  公开（公告）日：2015-05-20
• FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING
  申请人：Psyadon Pharmaceuticals, Inc.

  公开号：EP3057595A1

  公开（公告）日：2016-08-24
• Fused Benzazepines for Treatment of Tourette's Syndrome
  申请人：PSYADON PHARMACEUTICALS, INC.

  公开号：US20150164911A1

  公开（公告）日：2015-06-18

  The present invention encompasses methods of treating a subject who has been diagnosed as having a tic disorder or a movement disorder. The tic disorder can be Tourette's Syndrome, and the methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount of a composition comprising a D1/D5 receptor antagonist, a D1/D5 receptor partial agonist, or a mixture thereof. For example, the D1/D5 receptor antagonist can be ecopipam or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, structural analog, metabolite, or polymorph thereof.